



September 18-20, 2019

Dan Caesarea, Caesarea



## Thursday, 19 September 2019

09:00-09:45	Registration
09:45-10:00	Welcome
10:00-12:00	<b>Session 1: Familial Dyslipidemias</b>
<b>Chairpersons</b>	<b>Hofit Cohen</b> <i>Sheba Medical Center, Israel</i> <b>Euridiki Drogari</b> <i>Kapodistrian University of Athens, Greece</i>
10:00-10:25	Chylomicronemia Syndrome - causes and novel treatment options <b>Ettie Granot</b> <i>Kaplan Medical Center, Israel</i>
10:25-10:50	Familial Hypercholesterolemia in Greece: 25 years of experience through Cascade Screening" <b>Euridiki Drogari</b> <i>Kapodistrian University of Athens, Greece</i>
10:50-11:10	The characteristics of patients with probable Familial Hypercholesterolemia-screening a large payer/provider Healthcare Delivery System <b>Avishay Elis</b> <i>Rabin Medical Center, Israel</i>
11:10-11:25	Carotid IMT and plasma lipid levels among children and adolescents with familial hypercholesterolemia. A single center experience 2007-2019 <b>Hofit Cohen</b> <i>Sheba Medical Center, Israel</i>
11:25-12:00	Lysosomal acid lipase deficiency (LALD): real life clinical experience of treating a rare disease. <b>Dov Gavish</b> <i>Wolfson Medical Center, Israel</i> <b>Euridiki Drogari</b> <i>Kapodistrian University of Athens, Greece</i>
12:00-12:30	Coffee Break
12:30-14:00	<b>Session 2: Vascular and Cellular Biology of Atherosclerosis</b>
<b>Chairpersons</b>	<b>Joseph Roitelman</b> <i>Sheba Medical Center, Israel</i> <b>Kyriakos Kypreos</b> <i>University of Patras, Greece</i>
12:30-12:50	Inhibition of endothelial progenitor in the first 24 hours of an acute ischemic cerebrovascular event <b>Arnon Blum</b> <i>Bar Ilan University, Israel</i>
12:50-13:15	Paraoxonase1 endocytosis and activity in endothelial cells affects blood pressure <b>Andrea Szuchman-Sapir</b> <i>MIGAL- Galilee Research Institute, Israel</i>
13:15-13:40	Exploring glucolipototoxicity in pancreatic beta cells by combining advanced confocal analysis of the subcellular lipid map with proteomics <b>Shlomo Sasson</b> <i>The Hebrew University of Jerusalem, Israel</i>
13:40-14:00	The effect of ambient particulate matter on human adipose tissue <b>Lior Hassan</b> <i>Ben-Gurion University of the Negev, Israel</i>
14:00-15:00	Lunch and Poster Viewing
15:00-16:30	<b>Session 3: Lipid Metabolism, Fatty Liver</b>
<b>Chairpersons</b>	<b>Yehuda Kamari</b> <i>Sheba Medical Center, Israel</i> <b>Joachim Thiery</b> <i>Universitätsklinikum Leipzig, Germany</i>
15:00-15:20	NAFLD as a risk factor for CVD: Implications for therapy <b>Osama Hussein</b> <i>Ziv Medical Center, Israel</i>
15:20-15:45	The genetics of NAFLD: Focus on PNPLA3 <b>Yehuda Kamari</b> <i>Sheba Medical Center, Israel</i>





September 18-20, 2019

Dan Caesarea, Caesarea



15:45-16:10	A novel role for GAS3 in hepatic lipid metabolism <b>Hagai Tavori</b> Oregon Health & Science University, USA
16:10-16:30	Metabolic circuit involving free fatty acids, microRNA 122, and triglycerides <b>Chofit Chai</b> Sheba Medical Center, Israel
16:30-17:00	Coffee Break
17:00-19:00	<b>Session 4: A New Era in Lipid-Lowering Therapy</b>
<b>Chairpersons</b>	<b>Ofir Avizohar</b> Rambam Health Care Campus, Israel <b>Hagai Tavori</b> Oregon Health & Science University, USA
17:00-17:30	New Opportunities to Reduce Residual Risk Beyond Statin Therapy <b>Craig Granowitz</b> Amarin Pharma Inc. NJ, USA
17:30-17:50	Statin Therapy Among Chronic Kidney Disease Patients Presenting with Acute Coronary Syndrome <b>Sharon Shalom Natanzon</b> Sheba Medical Center, Israel
17:50-18:10	Applying antisense Technology to treat chylomicronemia and high Lp(a) <b>Dov Gavish</b> Wolfson Medical Center, Israel
18:10-18:35	Further analysis of recent PCSK9i Mega studies : Implications for clinical use <b>Gabizon Itzhak</b> Ben-Gurion University of the Negev, Israel
18:35-19:00	Innovation in CVD & T2D treatments from guidelines to clinical practice <b>Ronen Durst</b> Hadassah Hebrew University Medical Center, Israel



## Friday, 20 September 2019

08:00-08:30	Registration
08:30-08:45	Welcome
08:45-11:00	<b>Session 5: Diabetes, Obesity and Atherosclerosis</b>
<b>Chairpersons</b>	<b>Ilana Harman-Boehm</b> Ben-Gurion University of the Negev, Israel <b>Kevin Jon Williams</b> Temple University School of Medicine, USA
08:45-09:10	A novel pathway essential for canonical insulin and leptin signaling in hypothalamic neurons: a molecular explanation for simultaneous central resistance to the appetite-suppressing effects of two remarkably different hormones in obesity <b>Kevin Jon Williams</b> Temple University School of Medicine, USA
09:10-09:35	Risk factor for incident type 2 diabetes among adolescents- lessons from nationwide databases <b>Gilad Twig</b> Medical corps, Israel Defense Forces
09:35-10:00	Impact of HDL apolipoprotein composition on particle functionality, adipose tissue metabolic activity and glucose homeostasis <b>Kyriakos Kypreos</b> University of Patras, Greece
10:00-10:20	The prognostic impact of BMI trajectories after cardiac catheterization on long-term mortality <b>Elad Shemesh</b> Carmel Medical Center, Israel
10:20-10:40	Specific circulating micro-RNAs are associated with Type 2 Diabetes progression <b>Maya Sultan</b> Meir Medical Center, Israel
10:40-11:00	Inactivation of the E3 Ubiquitin Ligase IDOL attenuates diet-induced obesity and metabolic dysfunction in mice



**September 18-20, 2019**

**Dan Caesarea, Caesarea**



	Noam Zelcer <i>University of Amsterdam, The Netherlands</i>
<b>11:00-11:30</b>	<b>Coffee Break</b>
<b>11:30-14:00</b>	<b>Session 6: The new ESC dyslipidemia guidelines</b>
<b>Chairpersons</b>	<b>Yaakov Henkin <i>Ben-Gurion University, Israel</i></b> <b>Ian Graham <i>Trinity College Dublin, Ireland</i></b>
11:30-12:00	Evaluation of cardiovascular risk – comparison of the European and American cardiovascular risk scores <b>Ian Graham <i>Trinity College Dublin, Ireland</i></b>
12:00-12:30	Update on the new ESC Dyslipidemia Guidelines 2019 <b>Yaakov Henkin <i>Ben-Gurion University, Israel</i></b>
<b>12:30-13:15</b>	<b>Debate: What is the optimal LDL-c target goal in secondary prevention?</b>
12:30-12:45	An LDLc target goal of 70-100 mg/dL is sufficient <b>Morton Israel Leibowitz <i>Clalit Health Services · Research Institute</i></b>
12:45-13:00	LDLc should be lowered to less than 70 mg/dL <b>Dov Gavish <i>Wolfson Medical Center, Israel</i></b>
13:00-13:15	Re-battle and discussion
13:15-13:45	<b>Panel discussion – the new guidelines.</b> <b>Moderator: Yaakov Henkin <i>Ben-Gurion University, Israel</i></b> <b>Participants:</b> <b>Ian Graham <i>Trinity College Dublin, Ireland</i></b> <b>Yosef Rozenman <i>Wolfson Medical Center, Israel</i></b> <b>Marielle Kaplan <i>Rambam Health Care Campus, Israel</i></b> <b>Dr Lilach Maletzki <i>Ariel University, Israel</i></b>
<b>13:45-14:00</b>	<b>Rafael Bitzur Prize for Young Investigators</b>
<b>14:00-15:00</b>	<b>Lunch</b>